The Biopharma Credit (LON:BPCR) share price has risen by 3.37% over the past month and it’s currently trading at 0.9818. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will...
|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2016||2017||2018||2019||2020||2021E||2022E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
|Leverage (ttm)||Total||- Intang||+ Pension|
|Cash / Assets|
Latest News & Insights for BPCR
The Biopharma Credit (LON:BPCR) share price has risen by 1.04% over the past month and it’s currently trading at 0.97. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will co...
In the internet age, we face a daily blizzard of financial data. Successful investors know which numbers to track and how to ignore the noise. Some stocks excite investors by talking up future growth prospects that never quite come to...
BioPharma Credit PLC is a closed-ended investment company. The principal activity of the Company is to invest in interest-bearing-debt assets with a contractual right to future cash flows derived from royalties or sales of approved life sciences products. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve its investment objectives through direct or indirect exposure to debt assets. The Company's wholly owned subsidiaries include BPCR Ongdapa Ltd. and BPCR Limited Partnership. The Company's investment manager is Pharmakon Advisors L.P.
Latest News for BPCR
Upcoming Events for BPCR
Full Year 2021 BioPharma Credit PLC Earnings Release
BioPharma Credit PLC Annual Shareholders Meeting
As of Today at 07:04 UTC, shares in Biopharma Credit are trading at $0.99. This share price information is delayed by 15 minutes.
Shares in Biopharma Credit last closed at $0.99 and the price had moved by -0.51% over the past 365 days. In terms of relative price strength the Biopharma Credit share price has underperformed the FTSE All Share Index by -8.7% over the past year.
The overall consensus recommendation for Biopharma Credit is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Biopharma Credit dividend yield is 7.09% based on the trailing twelve month period.
Last year, Biopharma Credit paid a total dividend of $0.07, and it currently has a trailing dividend yield of 7.09%. We do not have any data on when Biopharma Credit is to next pay dividends.
We do not have data on when Biopharma Credit is to next pay dividends. The historic dividend yield on Biopharma Credit shares is currently 7.09%.
To buy shares in Biopharma Credit you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.99, shares in Biopharma Credit had a market capitalisation of $1.36bn.
Here are the trading details for Biopharma Credit:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: BPCR
Based on an overall assessment of its quality, value and momentum Biopharma Credit is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biopharma Credit. Over the past six months, its share price has underperformed the FTSE All Share Index by -2.67%.
As of the last closing price of $0.99, shares in Biopharma Credit were trading +1.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biopharma Credit PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biopharma Credit's management team is headed by:
- Harry Hyman - NEC
- Pedro de Cosio - IVM
- Martin Friedman - IVM
- Pablo Legorreta - IVM
- Colin Bond - NID
- Duncan Budge - NID
- Stephanie Leouzon - NID
- Rolf Soderstrom - NID